Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.82 |
| ▸ | CA2 | P00918 | 13/20 | 0.82 |
| ▸ | CA9 | Q16790 | 13/20 | 0.82 |
| ▸ | CA12 | O43570 | 12/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CA7 | P43166 | 1/20 | 0.70 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433421 | 0.90 | CA1 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL14372337 | 0.86 | CA1 (0.76) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4004795 | 0.86 | BAZ1A (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL668108 | 0.86 | CA1 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4009420 | 0.85 | MAPT (0.63) | CA1CA2CA9CA12MAPT | |
| SCHEMBL672734 | 0.85 | CA2 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4000903 | 0.84 | MEN1 (0.63) | CA1CA2CA9CA12MAPT | |
| SCHEMBL1395590 | 0.84 | CA1 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL12010913 | 0.83 | IDH1 (0.69) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4009962 | 0.82 | BAZ1A (0.59) | CA1CA2CA9CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2068857-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | CA1 1140/4885CA2 1678/4885CA9 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.